SIP
ANAC

Stoneridge Investment Partners’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Stoneridge Investment Partners’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-40,699
Closed -$432K – 256
2013
Q3 		$432K Buy
+40,699
New +$356K 0.09% 128

Other funds holding ANAC

RCP
Rho Capital Partners New York $20.4M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Stoneridge Investment Partners's ANAC Position: Q4 2013 in Review

Stoneridge Investment Partners sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q4 2013, closing a stake of 40,699 shares — an estimated $432K sold.

Stoneridge Investment Partners first reported a position in ANAC in Q3 2013 and held it in 1 quarter. The position peaked at $432K in Q3 2013. 87 funds tracked by Wall St. Rank hold ANAC as of Q4 2013.

  • Stoneridge Investment Partners reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q4 2013 after selling out during the quarter.
  • Stoneridge Investment Partners sold 40,699 ANACOR PHARMACEUTICALS INC COM shares in Q4 2013, an estimated $432K.
  • Stoneridge Investment Partners first reported a position in ANACOR PHARMACEUTICALS INC COM in Q3 2013 and held it in 1 quarter.
  • Stoneridge Investment Partners's ANACOR PHARMACEUTICALS INC COM position peaked at $432K in Q3 2013.
  • 87 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q4 2013.

Based on Stoneridge Investment Partners's 13F filing for Q4 2013, filed 14 Jan 2014.